Nanogel DDS enables sustained release of IL-12 for tumor immunotherapy.
Biochem Biophys Res Commun
; 367(2): 330-5, 2008 Mar 07.
Article
in En
| MEDLINE
| ID: mdl-18158918
ABSTRACT
For a valid cytokine immunotherapy of malignancies, a suitable delivery system that ensures slow-release of cytokines is required, because short half-life in vivo of the molecules ruins therapeutic efficacy while causing severe systemic toxic effects. We previously showed that the cholesterol-bearing pullulan (CHP)-based hydrogel nanoparticles, or nanogel, encapsulates, stabilizes and releases various molecules. Here we applied this nanogel to administration in vivo of interleukin-12 (IL-12). Recombinant murine IL-12 (rmIL-12) was successfully incorporated into CHP nanogel simply by incubated with CHP at room temperature. After subcutaneously injected into mice, the CHP/rmIL-12 complex led to a prolonged elevation in IL-12 concentration in the sera. Repetitive administrations of the CHP/rmIL-12, but not rmIL-12 alone, induced drastic growth retardation of preestablished subcutaneous fibrosarcoma without causing any serious toxic event. The present study proposes a novel therapeutic intervention technology, taking advantage of slow and sustained release of bioactive cytokines from the self-assembling biocompatible nanoparticles.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Interleukin-12
/
Delayed-Action Preparations
/
Nanostructures
/
Fibrosarcoma
Limits:
Animals
Language:
En
Journal:
Biochem Biophys Res Commun
Year:
2008
Document type:
Article
Affiliation country: